£600m funding call opens for UK biomedical research centres
£600m in funding is being allocated for an expansion in the network of biomedical research centres, a pillar of the UK's life sciences strategy.
AbbVie's ovarian cancer drug Elahere gets NHS green light
AbbVie's Elahere has become the first new NHS therapy in more than 20 years for resistant ovarian cancer, providing an alternative to chemotherapy.
NewLimit raises $435m for liver trials, and other financings
Longevity biotech NewLimit's $435m Series C heads this week's round-up of biotech venture capital financings.
Lilly strikes $1.9bn kidney disease alliance with Ascidian
In its third big licensing deal of the week, Eli Lilly has tapped RNA-editing specialist Ascidian for kidney disease therapies in a $1.9bn alliance.
ASCO26: Celcuity punished as trial disappoints investors
Celcuity is still confident it has a winner with its breast cancer treatment, gedatolisib, but investors seem less convinced by new VIKTORIA-1 data.
Sales & Marketing
Digital
Market Access
Oncology
Patients
R&D
Partner Content
Inizio Launches Intelligent Congress to Turn Event Investmen...
Inizio, the leading global commercialization partner to the health and life sciences industry, today announced the launch of Intelligent Congress
17th World ADC San Diego | October 12-15, 2026
The World’s Premier Forum to Advance Differentiated ADCs to Redefine Early-Line Oncology Patient Outcomes
6th Rare & Genetic Kidney Disease Drug Development Summit
The 6th Rare & Genetic Kidney Disease Drug Development Summit returns to Boston on August 18–20, 2026, bringing together global leaders advanc
Navigating Change: Key Industry Insights at PHARMAP 2026
PHARMAP returns in 2027 in Berlin, Germany, with Bayer as the Host Sponsor
Xcovery Partners with EVERSANA to Commercialize Lung Cancer ...
EVERSANA will provide comprehensive end-to-end commercialization services for Xcovery